ARCHIVES

Single-Agent Phase III Trial Comparing Vectibix to Erbitux Meets Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 36 No. 5 | May 31, 2013

Download PDF Visit The Full Archive

Related Articles

USC, Wisconsin Get Construction Grants Totaling $1.5 Million

March 23, 1990

NCI Programs: Pediatric Brain Tumor Grants Awarded

April 16, 1999

Targeting Men At High Risk Finds More Head & Neck Cancer

September 24, 2010

The Lancet Oncology Issues “Expression Of Concern” Over Paper

July 23, 2010

Bach: LCA Center Certification Untrustworthy; CISNET Models Don’t Match

May 9, 2014

DCPC Concepts OKd Include Nurse Research Training

May 25, 1984